- LOGIN
- MemberShip
- 2026-04-03 13:34:14
- Company
- ‘Should consider early use of effective new drugs for CML’
- by Son, Hyung Min Apr 17, 2025 05:57am
- Timothy Hughes, Professor of Hematology, South Australian Health and Medical Research Institute “Although various treatment options have emerged for chronic myeloid leukemia (CML), there is still unmet demand, as more than half of patients are intolerant. As CML treatment strategies are shifting to inducing a strong response in the early phase, it is important to prioritize the use of effective drugs.” Timothy Hughes, Professor of Hematology at the South Australian Health and Medical Research Institute, recently gave this assessment regarding CML treatment strategies during an interview with Dailypharm. The development of various tyrosine kinase inhibitors (TKIs), starting with Novartis' Gleevec, a first-generation targeted anticancer drug, in 2006, then the second-generation treatment options BMS' Sprycel, Novartis' Tasigna, Pfizer’s Bosulif, Il-Yang Pharmaceutical’s Supect, and the third-generation TKI Otsuka's Iclusig, has dramatically improved survival rates. However, since the existing first- to third-generation TKIs target the ATP binding site, there is a high possibility of developing resistance to mutations, which limits long-term treatment sustainability. In addition, as treatment options are limited for patients at risk of cardiovascular disease, there is a need for effective switching strategies and new treatment options in the third-line treatment space. Unlike existing treatment options, the fourth-generation TKI Scemblix is approved and mainly used as a third-line treatment for CML in Korea due to its specifically targeting the ABL myristoyl pocket t (STAMP) inhibition mechanism. Recently, it has been approved as a first-line treatment in Korea, the United States, and Europe, expanding its scope of use. Professor Hughes said, “We have seen a dramatic improvement in survival since the advent of TKI-based treatments, but many patients still experience treatment failure due to drug intolerance or resistance.” He added, “In particular, Scemblix is becoming an important alternative for patients who were contraindicated from using existing TKI treatment due to cardiovascular disease, etc.” Scemblix demonstrates superior efficacy in direct comparison studies with existing targeted therapies Scemblix has demonstrated its therapeutic improvement effect through a head-to-head study with existing targeted therapies. The clinical trial, ASC4FIRST, was the first study to compare Scemblix with standard first-line treatments currently available for newly diagnosed CML patients. The trial randomly assigned adult CML patients to the Scemblix group and the standard TKI treatment group and compared the major molecular response (MMR) rate at week 48. The results of the study showed that the MMR achievement rate at week 48 was 67.7% in the Scemblix-treated group and 49.0% in the standard TKI-treated group, showing an 18.9% difference. In terms of safety, the Scemblix-treated group showed a relatively low incidence of Grade 3 or higher adverse reactions, discontinuation rate due to adverse reactions, and dose adjustment and discontinuation rate for adverse reaction management compared to the control group. The biggest concern for TKI treatments, including Iclusig, which had been mainly used as a third-line therapy, was cardiovascular toxicity. Iclusig is known to have a tendency to increase the incidence of arterial occlusion depending on the dose. According to Professor Hughes, Iclusig should be used only in patients with no other treatment option because there have been many serious arterial system adverse reactions observed even at the standard dose of 45 mg per day. STAMP inhibitors have high target specificity as they act on the myristoyl pocket of the BCR-ABL1 protein, not the ATP binding site. Through this differentiated mechanism of action, Scemblix offers the advantage of maintaining a strong therapeutic effect while minimizing side effects. Professor Hughes commented, “Through the ASC4FIRST trial, Scemblix has demonstrated both efficacy and safety profiles superior to those of Gleevec, Tasigna, and Sprycel, which are currently used as first-line treatments for CML.” He went on to say, “In particular, Scemblix showed a higher MMR compared to Gleevec and also showed excellent results in terms of safety. The treatment discontinuation rate due to toxicity was also only half that of Gleevec. In addition, Scemblix also demonstrated higher treatment response rates and safety in the patient group compared to second-generation TKIs.” Potential rises for Scemblix as a first-line treatment option... “One step closer to treatment-free remission” #EB Professor Hughes believes that while CML treatment strategies have focused on improving survival in the past, it is now important to enable patients to achieve treatment-free remission and enjoy a 'life without need for treatment.' According to Professor Hughes, recent CML treatments tend to focus on inducing a strong response early, in the first-line treatment phase. This is because a fast and strong response induced by intensive treatment from the beginning can lead to a positive prognosis in the long term and ultimately increase the likelihood of achieving a treatment-free remission. Professor Hughes said, “Another notable agenda is that the treatment goal of patients is shifting to treatment-free remission. In fact, when patients are asked what treatment goal they most desire, most of them want to ‘no longer take medication.’ To date, the proportion of patients who have reached treatment-free remission is about 30%, but we expect that the figure will rise to more than 50% in the future through the use of STAMP inhibitors.” Professor Hughes believes that Scemblix has a high potential for use as a first-line treatment for CML. The ASCEND study, led by Professor Hughes, was the first Scemblix monotherapy clinical trial, involving approximately 100 patients. Professor Hughes explained that the results of the study were similar to those of the pivotal Scemblix clinical trial. “In Australia, ASCEND is currently undergoing a follow-up clinical trial. Patients who meet the criteria for participation are mostly enrolled in the study and receiving Scemblix as a first-line treatment,” added Professor Hughes. “For patients who are unable to participate in the trial, we are treating them with the best available option.” He went on to say, “Currently, the most important goal of first-line treatment is for patients to achieve a deep molecular response early and ultimately achieve a treatment-free remission. However, for patients who need to receive third line of treatment, the treatment goals will inevitably vary depending on the course and situation.” He said, “Scemblix has shown high safety and efficacy from the early stages of clinical trials. It is a drug that has shown the potential to be used not only as third-line treatment but also as first-line treatment.” He also emphasized, “We expect a strong therapeutic effect when Scemblix is used as a first-line treatment. If there were no restrictions set in our clinical trials, more than 90% of the patients may use Scemblix as a first-line treatment.”
- Company
- Vyndamax may be prescribed at tertiary hospitals in KOR
- by Eo, Yun-Ho Apr 16, 2025 05:55am
- Vyndamax, which was finally granted insurance reimbursement after 5 attempts, may now be prescribed in general hospitals. According to industry sources, Pfizer Korea's treatment for ATTR-CM (Tafamidis 61mg) passed the drug committees of 26 medical institutions nationwide, including the ‘Big 5’ major hospitals (Samsung Medical Center, Seoul National University Hospital, Asan Medical Center, Seoul St. Mary's Hospital, and Severance Hospital). Vyndamax was approved in Korea in August 2020 and has been granted reimbursement since March this year after a series of twists and turns. It failed its first reimbursement challenge in early 2021, Vyndamax failed to be designated as an essential drug at the time. In the first half of the same year, the company evaluated the drug’s cost-effectiveness and took on the second challenge through the risk-sharing agreement (RSA) track, just to meet the same results. In April 2022, it again failed to pass the Health Insurance Review and Assessment Service's Reimbursement Standard Subcommittee, but in July of the same year, it passed the subcommittee but was later judged non-reimbursable by the Drug Reimbursement Evaluation Committee 9 months later. At the time, the government and the pharmaceutical company were unable to reach an agreement on the risk-sharing plan. Pfizer again submitted a reimbursement application in June last year, passed the DREC review in October of the same year, and concluded a drug price negotiation with the National Health Insurance Service last month. The maximum insurance price ceiling for Vyndamax was set at KRW 100,000. Vyndamax is a separately licensed product that contains a different dose of the same ingredient as Vyndaqel, a treatment for familial amyloidotic polyneuropathy. Some view this as a strategy adopted by the pharmaceutical company to differentiate the drug price. However, it is encouraging that the drug was approved after 5 attempts over four years. Now, patients will only have to pay 10% of the drug price if the special calculation system is applied. The efficacy of Vyndamax was demonstrated through the Phase III ATTR-ACT study, where the drug reduced the incidence of cardiovascular events in patients with CM and showed an improvement in the six-minute walk test. In the ATTR-ACT study, 441 patients were randomly assigned in a 2:1:2 ratio to receive 80 mg of tafamidis, 20 mg of tafamidis, and placebo, respectively, and the primary endpoints of the study were hierarchical evaluation of all-cause mortality and frequency of cardiovascular-related hospitalization. The key secondary endpoints were the change from baseline to month 30 for the 6-minute walk test and the score on the Kansas City Cardiomyopathy Questionnaire–Overall Summary (KCCQ-OS), in which higher scores indicate better health status. Study results showed that tafamidis demonstrated a statistically significant reduction in all-cause mortality and frequency of cardiovascular-related hospitalizations compared to placebo.
- Opinion
- [Reporter's View] The MOHW’s contradiction
- by Lee, Jeong-Hwan Apr 16, 2025 05:55am
- The Ministry of Health and Welfare cited the 'non-face-to-face medical treatment pilot project' as an excellent administrative example last year. The reason for its excellence is that the non-face-to-face treatment, which was urgently and temporarily permitted in February 2020 in response to the COVID-19 pandemic, was converted into a pilot project in June 2023, 3 years later, and has been operated stably, with the pilot project model being supplemented and developed to improve the quality of medical services for the public. However, the MOHW overlooked the fact that in the process of implementing the non-face-to-face treatment pilot project, it revised and modified the scope of its application and permission several times, causing confusion among patients, medical institutions, pharmacies, and intermediary platforms. In particular, the MOHW also cited the Framework Act on Health and Medical Services as it failed to secure legal grounds, such as amendments to the Medical Service Act, in the process of converting non-face-to-face medical care into a pilot project in line with the government's declaration of the end of the COVID-19 pandemic. The MOHW's rationale for the pilot project was Article 44 of the Framework Act on Health and Medical Services, which states that “the national and local governments may conduct a pilot project if necessary to implement a new health and medical care system.” With just one line of legal provision as support, the MOHW conducted a non-face-to-face treatment pilot project that breaks the principle of face-to-face medical care. This is the background to the criticism that the opposition party, led by the Democratic Party of Korea, has leveled at the ruling party for forcing an executive order through politics on non-face-to-face medical care, which is directly linked to the health and lives of the people and has a significant impact on the domestic healthcare delivery system and pharmacy ecosystem. In fact, the MOHW has revised the guidelines for the pilot project 5 times since June 2023, when it converted non-face-to-face treatment into a pilot project. The model of the first pilot project, which divided medical institutions into clinics and hospitals and patients into returning and first-time patients, was criticized by the public as being overly complicated. This was also the time when some speculated that the MOHW Minister and Deputy Minister were reprimanded because the pilot project did not fully reflect former President Suk-Yeol Yoon’s request to consider ways to foster non-face-to-face treatment as its industry. Maybe due to this issue, the project for non-face-to-face treatment was revised to effectively remove the criteria on primary and follow-up visits on December 15, 2023, less than 6 months after its implementation. The reason put forward for revising the pilot project was to reduce the inconvenience raised by some in society and to expand patient access to medical care. Afterward, the Yoon administration’s policy on increasing the medical school capacity by 2,000 students was announced in 2024, and the scope of the pilot non-face-to-face treatment project was expanded under the pretext of “responding to the medical gap caused by the collective resignation of residents.” As a result, non-face-to-face medical care was allowed for more than the temporarily allowed period and was revised several times throughout the pilot project period, causing inconvenience to the public, medical institutions, and pharmacies as they had to constantly familiarize themselves with the changed standards and implementation plans. Even amid this confusion, the MOHW itself stamped its own excellent administrative seal because it had advanced the model of the non-face-to-face treatment pilot project, which is like giving itself a report card disjunct from the social confusion it had caused. Won-Joon Cho, a senior policy advisor for health and welfare from the Democratic Party of Korea, criticized the MOHW's full-scale expansion of the non-face-to-face treatment pilot project, saying, “Serious illegal activities are continuing. I will bring to account the background and responsibility for the unending pilot project in the future legislative process.” This is a glimpse of how the MOHW's ‘excellent administrative activity’ evaluation on its non-face-to-face treatment pilot project may be criticized during the National Assembly's audit and the bill review for the revision of the Medical Services Act. Non-face-to-face treatment is still being allowed without any legal basis. As the 22nd National Assembly is about to be inaugurated in a year and the country has entered an early presidential election due to the impeachment of the president, the MOHW should not issue a report card that contrasts with public opinion and the evaluation of the opposition party, but should instead work hard to sort out the problems identified in the process of revising the guidelines for the pilot project and prepare a legislative bill that can minimize social confusion.
- Company
- Tepmetko targets rare lung cancer target with reimbursement
- by Whang, byung-woo Apr 16, 2025 05:55am
- Merck is seeking to increase the market influence of Tepmetko (tepotinib), which was granted reimbursement 3 years after its approval, by improving treatment access. Although the MET mutation is a rare mutation that occurs in 1.8-3.1% of non-small cell lung cancer patients in Korea, it is evaluated that the drug’s reimbursement will have a significant effect as it increases the success rate when early diagnosis and appropriate treatment are carried out. Ji-Youn Han, professor of Hemato-Oncology at the National Cancer Center, On the 15th, Merck Biopharma Korea held a press conference to shed light on the implications brought by Tepmetko’s reimbursement, a treatment for non-small cell lung cancer with MET exon 14 deletion mutation. In Korea, MET mutations in non-small cell lung cancer are known to cause resistance to other anticancer treatments and have a high rate of metastasis to bones, the brain, etc., which is associated with poor patient prognosis. In addition, most patients are elderly, which lowers the response rate to immuno-oncology drugs, and most patients relapse within 5 months. “MET-mutated non-small cell lung cancer has a poor prognosis, and brings threefold increased risk of death compared to those without mutations,” said Ji-Youn Han, a professor of Hemato-Oncology at the National Cancer Center, who presented at the press conference. ”Most patients are elderly, have a low response rate to immuno-oncology drugs, and have difficulty tolerating strong side effects, so there was a high unmet need for MET-mutation targeted therapies.” Tepmetko’s reimbursement was based on the Phase II VISION study in patients with MET-mutated NSCLC. In the 32.6-month follow-up of 313 patients diagnosed by liquid biopsy or tissue biopsy, Tepmetko showed an objective response rate (ORR) of 58.6%, median progression-free survival (PFS) of 15.9 months, median overall survival (OS) of 29.7 months, and median duration of response (DoR) of 46.4 months in patients diagnosed by tissue biopsy and with no previous treatment experience. These results were consistent regardless of treatment line, biopsy method, etc., and showed consistent efficacy in Asian patients, including Koreans. In a subgroup analysis of 106 Asian patients, the ORR of patients who were initially treated with Tepmetko was 64%, with a median PFS of 16.5 months, a median OS of 32.7 months, and a median DoR of 20.7. “The importance of personalized treatment based on MET mutations is being emphasized in the non-small cell lung cancer setting. Tepmetko has demonstrated consistent effects regardless of the treatment line in Asians,” said Professor Han. Although Tepmetko has demonstrated its effect through clinical results, the company had to jump over high hurdles to be included in the reimbursement list. After failing to set the reimbursement criteria twice, including during the Health Insurance Review and Assessment Service's Cancer Disease Review Committee meeting, the company voluntarily withdrew its reimbursement application, and submitted a new application in July last year, which led to the current result. As a result, Tepmetko became the first treatment option in the same class to be listed for reimbursement, ahead of Tabrecta (capmatinib), an anticancer drug that was approved in Korea at the same time in 2021. Currently, Tepmetko is expected to quickly settle into the prescription environment as it has passed the Drug Committees (DCs) of more than 30 medical institutions nationwide, including the Big 5 tertiary hospitals such as Samsung Medical Center and Seoul National University Hospital. “From the perspective of a doctor treating patients in the clinical setting, we need more treatment options to keep patients alive and improve their quality of life,” said Professor Han. ”I think this coverage of Tepmetko is a positive step because it means patients can use it without financial burden.” “We hope that this reimbursement of Tepmetko will play an important role in the future treatment environment in Korea,” said Christoph Hamann, General Manager of Merck BioPharma Korea. ”Merck will continue to endeavor to drive innovation at the forefront in the field of cancer treatment and will continue to strive to improve the intractable cancer treatment environment.”
- Policy
- Will a 'Duodart' generic for prostatate drug be available?
- by Lee, Hye-Kyung Apr 16, 2025 05:55am
- Product photo of Duodart A generic version of GSK's benign prostatic hyperplasia (BPH) combination product 'Duodart Capsule (dutasteride·tamsulosin hydrochloride),' which drove the success of the combination drug market for urology in Korea, is now under development. On the 14th, the Ministry of Food and Drug Safety (MFDS) approved an open-label, randomized, two-group, two-period, fasting, single-dose, oral, crossover study in healthy adult male subjects for the biological equivalence evaluation of Aprogen Biologics' 'Dutatams Capsule' and the original 'Duodart Capsule.' Duodart is a fixed-dose combination of the 5α-reductase inhibitor dutasteride and the α‑blocker tamsulosin, which was first approved in Korea in 2021. It was subsequently listed on the reimbursement drug list the following year. According to market research firm UBIST, Duodart surpassed KRW 10 billion in outpatient prescription sales in its second year of market launch in 2023 and reached KRW 23.2 billion last year. Until earlier this year, before four fixed-dose combination products of dutasteride and tadalafil were released, the prostate hyperplasia combination market was considered unchallenged. Apart from Duodart, Hanmi Pharmaceuticals had launched 'Gugutams,' a product combining tamsulosin and tadalafil. Despite various ingredients such as tamsulosin·finasteride·dutasteride for prostate hyperplasia treatment; mirabegron·solifenacin for overactive bladder treatment; and sildenafil·tadalafil for erectile dysfunction having lost their patents, there had been no updates to new fixed-dose combinations launches. Among these, only Duodart was performing well. Duodart is designed for the treatment of moderate to severe BPH and is administered orally once daily as a single capsule. Combining the two active ingredients into one capsule achieves rapid symptom improvement and reduces the long-term risks associated with disease progression. Furthermore, it minimizes dosing frequency, improves patient adherence, such as the likelihood of missed doses, and simplifies treatment regimens.
- Policy
- Global pharma proposes 'indication-based pricing system'
- by Lee, Jeong-Hwan Apr 16, 2025 05:55am
- Overseas global pharmaceutical companies with subsidiaries in Korea are currently voicing the adoption of policies aimed at resolving 'reimbursement inequities' for therapies for severe and rare diseases and implementing an 'indication-based pricing system' amid an early presidential election. While the Korean government maintains that an indication-based pricing system should be carefully reviewed over the long term due to various potential challenges, global pharmaceutical companies have begun gathering public opinion on the issue at a parliamentary forum. On the 15th, Rep. Seo Mi-hwa of the Democratic Party, a National Assembly's Public Healthcare Committee member, is preparing to hold a 'Discussion Forum on Resolving Inequalities in Innovative New Drugs and Regulatory Reforms.' It is intended to highlight that only 22% of innovative new drugs, such as those changing the treatment paradigm for severe and refractory diseases like cancer drugs, are reimbursed in Korea, leaving patients without timely access to therapies. In particular, the forum will also discuss measures to introduce an indication-based pricing system in Korea to expand reimbursement for new drugs. The introduction of an indication-based pricing system was an issue raised by the Korea Research-Based Pharma Industry Association (KRPIA), which requested a pilot project from the Ministry of Health and Welfare (MOHW) and other government agencies overseeing national health insurance. The KRPIA requested that the government initiate a pilot project applying a 'weighted average price by indication' and 'differentiated reimbursement rates by indication' for drugs under risk-sharing agreements (RSA). Furthermore, KRPIA is reportedly planning to propose to the candidate camps of parties such as the Democratic Party and the People Power Party policies to expand patient treatment opportunities through the implementation of an indication-based pricing system during this early presidential election cycle. The request is based on the fact that some overseas countries, including Italy, France, and Switzerland, are already implementing policies that evaluate the therapeutic value of drugs with multiple indications separately by indication, by determining different insurance prices or applying differential discounts at reimbursement. The KRPIA is urging these measures to be adopted as a commitment to enhancing patient access to medications. The request aligns with a presidential policy proposal that will coincide with a parliamentary debate later this month. However, the MOHW has stated that the indication-based pricing system should be carefully reviewed from a long-term perspective. While they agree with the rationale for introducing the system, the MOHW believes that further long-term discussions are necessary, such as financial impact analysis, establishment of legal grounds, and development of billing and settlement systems to prevent circumvention and distorted prescribing practices among some patients, must be addressed first. The rep. office responsible for preparing for the forum stated, "At the discussion forum, we will look for solutions to the prolonged processing period following reimbursement listing and the delays in reimbursement payments occurring within the approved indications," and added, "We will review the regulatory improvement policy agenda from the perspective of treatment disparities among patients."
- Company
- Orphan drug 'Thio Spal-P' avoids approval cancellation
- by Kim, Jin-Gu Apr 15, 2025 05:55am
- A rare disease treatment, 'Thio Spal-P Inj (thiotepa),' faced narrow escape from receiving approval cancellation. According to pharmaceutical industry sources on the 11th, the Seoul Administrative Court ruled in favor of Dongin Pharm against the Ministry of Food and Drug Safety (MFDS), ruling a 'plaintiff victory' on the 10th. Dongin Pharm filed a suit in the administrative court arguing that the MFDS' administrative measure related to the cancelation of imported item approval in May last year. This rare disease treatment is used as a premedication regimen before autologous·allogenic stem cell transplantation in adult·pediatric patients with hematological diseases. It is also used when high-dose chemotherapy in combination with stem cell transplantation is adequate for treating adults·pediatric patients with solid cancers. This type of drug, with imported annual sales below KRW 200 million, faced several hurdles. Initially, a medical device company imported a product called 'Thiotepa,' manufactured by US-based pharma company Bedford and distributed in South Korea. However, concerns have been raised in the United States that environmental waste and carcinogens are hugely produced during the production of Thiotepa. Therefore, the US-based manufacturer discontinued production of this drug, leading to discontinued import by the Korean importing company. After that, the Korea Orphan Drug & Essential Drug Center responded. The Korea Orphan Drug & Essential Drug Center secured 'Tepadina Inj' from Italia and began distributing in South Korea. Then, Korean companies also began importing this drug. Dongin Pharm received approval for the imported product 'Tepadina Inj 15mg·1g' with the same active ingredient. This drug soon became included in the National Health Insurance reimbursement list. On May 21st, the MFDS issued an administrative measure of cancellation of imported product approval for this drug. The Ministry of Health and Welfare (MOHW) announced that the reimbursement of this drug will be discontinued the next day due to the decision of approval cancellation by the MFDS. The announcement to suspend reimbursement was reversed within a day. On that same day, the MOHW announced that the reimbursement status for this drug would be maintained. The decision was made in response to a notification from the administrative court indicating that a suspension of execution had been filed. It was due to Dongin Pharm filing a suspension of execution and an administrative suit. In response to MFDS giving a cancelation measure of imported product approval, Dongin Pharm immediately filed a suit for withdrawing such measure and applied for suspension of execution until the ruling. The court accepted the application for suspension of execution. The lawsuit lasted over a year. Dongin Pharm and MFDS appeared in court three times since September 2024 to argue whether cancellation measure of the imported product is appropriate. Ultimately, the Seoul Administrative Court ruled in favor of Donging Pharm. Therefore, Dongin Pharm, which imports Thio Spal-P, was relieved. However, the MFDS has yet to decide whether to appeal. In South Korea, three companies have received approval for imported rare disease treatments containing thiotepa. Two pharmaceutical companies are distributing these drugs to South Korea, excluding a company without any import record. However, Thio Spal-P is the only drug that is in injectable formulation.
- Company
- Daehwa Pharmaceutical's Liporaxel aims for listing in China
- by Nho, Byung Chul Apr 15, 2025 05:55am
- The world's first oral paclitaxel, Liporaxel, for gastric cancer, is expected to enter the first negotiation step with the Chinese health authority in June for health insurance listing. The negotiation outcome gains attention. Daehwa Pharmaceutical's Liporaxel is sold in local Chinese hospitals at approximately KRW 940,000 per 30 mg. Sources said that this drug's anticipated reimbursement price will likely range KRW 400,000-450,000. The global market for paclitaxel injectables is valued at roughly KRW 5 trillion, of which China accounts for approximately 40–50%, making it a critical battleground for drug launches. Liporaxel obtained marketing approval in September 2024 from the China National Medical Products Administration (NMPA) for the indication of gastric cancer and began a full-scale launch centered in Shanghai around March. Until the development of Liporaxel solution in 2016, paclitaxel formulations had been prescribed only in injectable form. The oral liquid formulation of Liporaxel, a gastric cancer treatment, secured the status of the world's first improved drug converted from an injectable to a liquid formulation, and if reimbursement is achieved in China, its ease of administration is expected to drive rapid growth. Conventional paclitaxel intravenous (IV) treatments typically require more than three hours of infusion time, including pre-treatment, so launching a formulation-changed product has been a long-awaited goal for academia and patient groups. The mechanism of action of Daehwa Pharmaceutical Furthermore, in clinical trials for gastric cancer, the new formulation showed improved outcomes compared to IV therapy, particularly in terms of side effects such as hair loss and peripheral neuropathy, which is expected to enhance patient convenience and safety greatly. Notably, by reducing the treatment time, this drug is expected to provide more patients with the opportunity to receive treatment, thereby improving the overall efficiency of cancer care. Liporaxel demonstrated equivalent safety and efficacy compared to a control drug in a Phase 3 trial conducted in approximately 550 gastric cancer patients in China. Meanwhile, Liporaxel was licensed in September 2017 to China's RMX Biopharma under a contract that included a licensing fee of USD 25 million (approximately KRW 33.2 billion) along with separate sales royalties, and the rights for Liporaxel as a second-line treatment for advanced, metastatic, or locally recurrent gastric cancer in the markets of China, Taiwan, Hong Kong, and Thailand are held by Haihe Biopharma.
- Company
- BD experts in demand due to increasing global partnerships
- by Whang, byung-woo Apr 15, 2025 05:54am
- Due to increasing technology transfer and partnership opportunities in the pharmaceutical and biotech industries, the role of business development (BD) is becoming increasingly important. Also, demand is growing for the ability to move beyond R&D that advances science-based technologies to securing actual deals. BD is a position that identifies and introduces promising technologies or new products based on domestic and international market analysis and creates business opportunities such as technology transfer, strategic alliances, and joint research. This means that it is a key department that brings in new products or drives partnerships that will drive company growth, and it is directly tied to the export (licensing out) of new technologies. Domestic pharmaceutical and bio companies are achieving success and making licensing out deals overseas, thanks to increased investment in new drug development. In fact, in 2019, there were 14 licensing-out deals (worth about KRW 8.5 trillion) in Korea, and in 2021, the number of contracts reached 31, a threefold increase from the previous year, setting a new record. In particular, large-scale licensing deals are emerging, whose upfront payments exceed KRW 1 trillion per technology, although their milestone achievement progress remains to be seen. As pharmaceutical companies, which used to focus on the domestic market, are entering the global stage, the BD department is becoming at the forefront of business development, transferring technology to overseas partners and leading joint development, which is adding strength to the growing view that BD capabilities directly affect corporate competitiveness. In fact, domestic bio companies are strengthening their strategy of developing their own products from the non-clinical to early clinical stages and then licensing them out. Specifically, they are actively pursuing entry into the global market by establishing overseas subsidiaries and hiring local BD personnel. " “Lack of experience is the biggest challenge” ... Systematic training is essential. The problem is that domestic companies are still facing difficulties in the global BD process, due to the lack of negotiating power, lack of experience in evaluating technology value, and lack of global communication experience. A representative of Pharma Ventures, who the reporter met at the 2025 Young BD Workshop hosted by the Korea Drug Development Fund (KDDF), expressed disappointment in the “storytelling” poser of Korean companies. “Korean companies have very good scientific capabilities and technology, but they often fail to develop their assets to the level required by global big pharma,” said a Pharmaventures official. ”Companies often concentrate on a single pipeline, so when if they license out their technology, the company's is virtually just giving out their whole value.” It is also important to reduce the gap between investors and Korean companies when it comes to technology transfer and deal-making, but it is often assessed that Korean companies cannot translate science into 'value and business opportunities'. Ultimately, for Korean companies to find opportunities overseas, in addition to R&D, there is a growing need to develop specialized personnel who can turn these into commercial opportunities. In the pharmaceutical and biopharmaceutical industry, there is a common view that, as the saying goes, “it's all about people,” and that talent investment is important for new drug development. However, there is also a realistic point of view that there are still not enough educational opportunities to systematically train BD talents. In particular, young BD managers with 1-5 years of experience are in very high demand for training to strengthen their expertise, as they work in an environment where it is difficult to gain practical experience. In this situation, the 2025 Young BD Workshop held by KDDF in early April sought to foster the next generation of BD talent. Young-min Park, head of the National New Drug Development Project Team This event is a successor to the BD talent development workshop that began in 2018 through the pan-ministerial new drug development project and is a program that focuses on young BD practitioners in their first to fifth years to develop practical global technology transfer capacity. Young-min Park, head of the National New Drug Development Project Team, said, “A sophisticated commercialization strategy is needed from the early stages for successful new drug development. I hope this workshop will serve as a stepping stone for fostering young BD talents with expertise and practical capabilities that meet global standards.” With KDDF at the forefront, BD is responsible for the company's future growth engines, such as closing new product licensing agreements and building partnerships in the long term. As such, the company is showing a consensus on securing and cultivating talent. An industry official added, “I think the cultivation of BD talent is an important factor that can turn Korea's quality technology into commercial success. I think that the education and efforts related to BD, along with the cultivation of various talents in the pharmaceutical and bio sector, will play a major role in creating a Korean bio ecosystem in the future.”
- Policy
- DPK’s election pledge includes substitution dispensing
- by Lee, Jeong-Hwan Apr 15, 2025 05:54am
- The Democratic Party of Korea will include a policy to support domestically developed new drugs through a drug pricing system that links the investment rate (amount) of research and development (R&D) by pharmaceutical companies with a drug’s insurance price ceiling and drug price reduction rate in its presidential election pledge. DPK’s intention is to lead the development of the pharmaceutical and bio-industry, which is a future growth engine for the country, by enabling pharmaceutical companies that are constantly striving to evolve and create new drugs to benefit from the government's efforts rather than those intent on generic sales. In particular, since the Korean pharmaceutical industry is still dominated by generic drug manufacturing, the Democratic Party of Korea is also looking into whether maintaining the current tiered drug pricing system would be of practical help to the industry's development. The DPK is also considering ways to reasonably legislate the Seok-yeol Yoon administration's pilot project for unlimited non-face-to-face medical care and ways to resolve the supply and demand instability of medicines, including the promotion of alternative dispensing, to adopt them as presidential campaign pledges. Recently, Won-Joon Cho, the senior expert advisor for health and welfare at the Democratic Party of Korea(and the head of the presidential election pledge task force for the policy committee) held a meeting with the Press Corp and revealed the direction of the presidential election pledges related to the pharmaceutical and bio-industry and the health industry. ◆Pharmaceutical and bio-industry promotion measures=The Democratic Party of Korea (DPK) agreed that the pharmaceutical and bio-industry is an industry that drives future growth of South Korea, but also recognized that it is a field that has a dual nature that requires regulation due to safety concerns. This is why there are differences in the views of pharmaceutical and bio industries among government ministries such as the Ministry of Health and Welfare (MOHW), the Ministry of Food and Drug Safety (MFDS), the Ministry of Science and ICT, and the Ministry of Trade, Industry and Energy (MOTIE). In this situation, Cho said, “The Democratic Party of Korea will definitely improve unnecessary administrative procedures or excessive regulations that hinder the promotion of the pharmaceutical and bio-industry and the creation of new domestic drugs. However, we will make sure that excessive deregulation does not lead to distrust of products or the industry as a whole.” This is because the pharmaceutical industry is directly linked to the lives and safety of the people, and at the same time, it has the special characteristic of being the future food of the nation. Cho said that he has been preparing pledges based on 3 principles: ▲expanding investment and support, ▲reorganizing the current support system, and ▲strengthening social responsibility to promote the pharmaceutical and bio industry. “We will come up with a concrete performance-based R&D policy and adopt a system that rewards drug prices in proportion to the R&D investment ratio,” said Cho, adding, ”We are also paying attention to the opinion that the tiered drug pricing system needs to be improved to make it more intuitive and reasonable.” He added, “Even when a pharmaceutical company wants to contribute to society, in many cases, the scope is narrow. We are considering making pledges to support the diversification of social contribution methods by improving the innovative pharmaceutical company certification system, among others. We will include a policy to support pharmaceutical companies that export domestically produced new drugs overseas, rather than for Korea’s industry structure built around generics, as our presidential election pledges.” In particular, he said, “As we operate a generic-based industrial structure, there is a side to the issue of illegal rebates that cannot be abolished no matter how much the system is improved. I believe we should put support for overseas expansion and export pharmaceuticals into a separate package of pledges. There are also big concerns in the pharmaceutical industry about the Trump administration, and DPK is looking at countermeasures for the pharmaceutical industry from a broader perspective of trade.” ◆Seeking solutions to the instability of non-face-to-face medical care and drug supply = Cho said that DPK escapes criticism that it pretends to seek progressive politics but is hindering technological progress. The point is that DPK often has to consider what attitude it should take when faced with social and public demands for medical policies that are integrated with the IT industry, such as non-face-to-face medical care. Nevertheless, Cho emphasized that healthcare policies that are closely related to the health and lives of the people cannot be focused solely on fostering and promoting them as an industrial framework. The current government was criticized for conducting non-face-to-face medical care as a tool for industrial development for an unlimited period - for years - based on the enforcement decree without amending the law, which is regarded abnormal. “The healthcare sector is also making technological progress together with the high-tech IT industry. However, due to the nature of healthcare, if the basic premise of public safety is not secured, the foundation of the policy may be shaken,” said Cho. ”It is difficult to lead healthcare policy with an overly industrial frame. However, it is necessary to make pledges that reflect the reality and accept new systems and environmental changes with a flexible attitude.” He also criticized the former government, saying, “IT was a pilot project, so the biggest problem was that it is allowing non-face-to-face medical care that goes beyond the actual project without any legal basis.” He added, “There were no restrictions on the target, standards, scope, region, or time limit. I have never seen a pilot project like this. Serious illegal activities are continuing.” In response, the Democratic Party said that it will establish a legal basis as soon as possible so that the principle of non-face-to-face medical care can be established in this presidential election, and will hold the current government accountable for the background of the pilot project. “The policy-making process that led to the current pilot project should be thoroughly investigated and held accountable,” said Cho, ”Non-face-to-face medical care is intended to supplement the public's access to medical care, but the results of the pilot project have become a tool and a window for prescribing anti-hair loss drugs and emergency contraception. It is being used in a way that is completely different from its original purpose.” Regarding DPK’s direction for legalizing non-face-to-face medical care, he said, “Legislation is needed that includes not only the target, scope, and standards, but also the management and supervision of intermediary platforms. Delivery of medicine is not an immediate problem. It is not too late to decide on this issue when the basis for the Medical Service Act for Non-face-to-face medical care is created and additional discussions on the Pharmaceutical Affairs Act are held.” He also added, “We need to think about whether to adhere to the principle of non-face-to-face medical care that DPK proposed for the 21st National Assembly. This is because we cannot ignore the fact that many people have experienced or are using non-face-to-face medical care.” He also emphasized, “Even if we adopt the principle of allowing only people with limited mobility and residents of remote areas, the law should cover areas where there is a great social demand, such as pediatric patients.” Finally, regarding the issue of instability in the supply of pharmaceuticals, he summarized it as “It is still a difficult problem to solve and an urgent task. Policy-wise, we need to come up with alternatives.” “It is important to decide what policy agenda to adopt to address the issue of supply and demand instability. For example, the ingredient-specific prescription is a very sensitive issue between different medical schools, so it is politically difficult to tackle,” said Cho. ”We will introduce the agenda of vitalizing substitute dispensing, which is inevitable to resolve supply and demand instability, even if we would need to discuss the conflict that may arise in the future.” He added, “There will be more and more direct conflicts over the scope of practice, and the DPK will strengthen the governance structure under the Healthcare Workforce Support Act to achieve consensus and social compromise among the professions in a consultative body with the participation of the relevant parties.” This is interpreted as the party’s intention to actively utilize the Healthcare Workforce Scope Adjustment Act, which is pending in the Legislative and Judicial Committee, initiated by Democratic Party member Yoon Kim.
